Atrial Fibrillation Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with symptomatic persistent atrial fibrillation (an irregular heart rhythm lasting longer than 7 days but less than 12 months), confirmed by a doctor's notes and a heart tracing (ECG).
• People who have been assessed as a suitable candidate for a catheter ablation procedure (a treatment that uses energy to correct abnormal heart rhythms).
• Adults between 18 and 80 years of age.
• People who are willing and able to attend all required check-ups and assessments for the full duration of the study.

Who may not be able to join:

• People whose atrial fibrillation is caused by an underlying treatable condition, such as thyroid disease, an electrolyte imbalance, acute alcohol intoxication, or another reversible or non-heart-related cause.
• People who have previously had an ablation procedure or surgery on the left side of the heart, including procedures to close a hole in the heart or seal off the left atrial appendage.
• People who have had heart valve surgery or a procedure involving the heart valves, or who have an artificial heart valve.
• People who have had a carotid artery stent or carotid artery surgery.
• People who have had any heart procedure (surgical or via a catheter) within the 90 days before the start of the study.
• People who have had coronary artery bypass graft (heart bypass) surgery within the 6 months before the start of the study.
• People who are scheduled for a heart transplant or other heart surgery within 12 months after the planned ablation procedure.
• People who have had a stroke or a mini-stroke (transient ischemic attack) within the 6 months before the start of the study.
• People who have a blood clot found in the left upper chamber of the heart on a scan.
• People with a history of abnormal blood clotting or bleeding disorders.
• People who have a medical reason that prevents them from taking long-term blood-thinning medication.
• People who have had a heart attack within the 3 months before the start of the study.
• People with a Body Mass Index (BMI) greater than 40.
• People whose left upper heart chamber is larger than 55 mm in a specific measurement taken on imaging (confirm with trial site).
• People who have been diagnosed with a benign heart tumour called an atrial myxoma.
• People with uncontrolled heart failure, or heart failure classified as severe (NYHA Class III or IV) (confirm with trial site).
• People with rheumatic heart disease.
• People with a thickened heart muscle condition called hypertrophic cardiomyopathy.
• People with unstable chest pain (unstable angina).
• People with moderate to severe narrowing of the mitral heart valve.
• People with severe leaking of the mitral heart valve, based on specific measurements taken on imaging.
• People with primary pulmonary hypertension (high blood pressure in the lungs not caused by another condition).
• People with significant lung disease or a chronic breathing condition.
• People with kidney failure who need dialysis.
• People with a history of severe acid reflux disease (GERD) that required surgery or a mechanical procedure to treat.
• People who are currently acutely unwell, have an active infection, or have sepsis.
• People who are unable to have both a CT scan and an MRI scan.
• People with a significant birth defect or medical condition that, in the opinion of the study doctor, would interfere with participation or the reliability of the study results.
• People who are currently participating, or plan to participate, in another clinical study of a drug, device, or biological treatment during this study, unless pre-approved by the study sponsor.
• People who have a blood clot, tumour, or other abnormality that would make it unsafe to insert or move the catheters needed for the procedure.
• People with a known dependency on drugs or alcohol.
• People whose life expectancy is less than 12 months.

Important: Always verify eligibility with the trial site directly before applying.